All In Biotech

Drug Trial Radar · NCT04695327

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy

A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jan 11, 2021

Primary completion

Sep 3, 2025

Study completion Sep 3, 2025

Sponsor

Lead sponsor
TILT Biotherapeutics Ltd.Industry
Sponsor type
Industry
First posted
Jan 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.

Conditions

  • Solid Tumor

Interventions

  • TILT-123Biological

    TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with any (serious and non-serious) Adverse Events.Time frame: 85 days
  2. Number of Participants with abnormal laboratory values.Time frame: 85 days
  3. Number of Participants with vital sign abnormalities.Time frame: 85 days
  4. Number of Participants with Adverse Events assessed by 12- lead electrocardiograms (ECGs)Time frame: 85 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Helsinki University Hospital

    Helsinki, Uusima, Finland

  • Docrates Cancer Center

    Helsinki, Uusima, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.